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ABSTRACT
Objective: Human epididymis protein 4 (HE4) is a validated, complementary biomarker to cancer anti-
gen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently, there are insufficient data
on the utility of longitudinal HE4 measurement during HGSC treatment and follow up. We set to pro-
vide a comprehensive analysis on the kinetics and prognostic performance of HE4 with serial measure-
ments during HGSC treatment and follow up.
Methods: This prospective study included 143 patients with advanced HGSC (ClinicalTrials.gov identi-
fier: NCT01276574). Serum CA125 and HE4 were measured at baseline, before each cycle of chemo-
therapy and during follow up until first progression. Baseline biomarker values were compared to the
tumor load assessed during surgery and to residual disease. Biomarker nadir values and concentrations
at progression were correlated to survival.
Results: The baseline HE4 concentration distinguished patients with a high tumor load from patients
with a low tumor load assessed during surgery (p<.0001). The baseline CA125 level was not associated
with tumor load to a similar extent (p¼.067). At progression, the HE4 level was an independent pre-
dictor of worse survival in the multivariate analysis (p¼.002). All patients that were alive 3 years post-
progression had a serum HE4 concentration below 199.20pmol/l at the 1st recurrence.
Conclusion: HE4 is a feasible biomarker in the treatment monitoring and prognostic stratification of
patients with HGSC. Specifically, the serum level of HE4 at first relapse was associated with the survival
of patients and it may be a useful complementary tool in the selection of second line treatments. This
is to the best of our knowledge the first time this finding has been reported.
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Epithelial ovarian cancer is an umbrella term that includes a
heterogeneous group of malignancies, of which high grade
serous ovarian carcinoma (HGSC) is the most common and
aggressive [1]. The survival rate of patients diagnosed with
HGSC is poor (43% 5-year survival), mostly due to diagnosis
at a late stage [1]. The main pillar in primary HGSC treatment
is the surgical removal of all visible tumor (complete cytore-
duction) followed by platinum based chemotherapy [2]. The
implementation of precision drugs, specifically poly (ADP-
ribose) polymerase (PARP)-inhibitors and bevacizumab, has
been proven feasible in improving the survival of patients
[3,4]. Although an adequate treatment response is generally
obtained, most patients relapse and eventually develop a
therapy-resistant end-stage disease [5].
In the clinical setting, cancer antigen 125 (CA125) is cur-
rently the only biomarker widely used in the diagnosis and
treatment monitoring of HGSC [6]. The limitations of CA125
are well-known, and include insufficient detection of early
stage disease, the presence of small amounts of tumor
regardless of CA125 normalization, and the increase of serum
CA125 in other cancers and benign conditions [7]. Several
studies have been conducted on the prognostic capacity of
CA125 with conflicting results: there is evidence on the utility
of preoperative serum CA125 level in predicting cytoreducti-
bility [8,9], but contradictory results have also been reported
[10,11]. The shortcomings of CA125 and the insidious nature
of HGSC have sprouted comprehensive research on more
satisfactory biomarkers in the diagnosis, treatment monitor-
ing, and follow up of the disease [12]. Human epididymis
protein 4 (HE4) was first described by Kirchhoff et al. [13],
and it has since been proposed as a complement to CA125
in the diagnosis of HGSC [14].
At present, there is promising, but insufficient evidence
on the prognostic abilities of HE4 both in predicting optimal
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cytoreduction and cancer survival [15–18]. However, there
has also been conflicting results [19], and currently there is
no consensus on the clinical use of HE4 in the treatment
monitoring and follow up of HGSC and the routine measure-
ment of HE4 is not advocated to this end [20]. Overall, there
is a need for a comprehensive evaluation on the utility of
HE4 throughout the treatment regimen of HGSC. In the cur-
rent study, we evaluated the feasibility of HE4 in the treat-
ment monitoring and prognostic stratification of HGSC by
analyzing longitudinal serum HE4 concentrations.
Material and methods
Study population
This prospective study was conducted during 2009–2019 at
the Turku University Hospital with the approval of the Ethics
Committee in the Hospital District of Southwest Finland
(ETMK 102 53/180/2009). The study was designed to evaluate
biomarkers in the treatment monitoring of epithelial ovarian
cancer (ClinicalTrials.gov identifier: NCT01276574) and 143
patients with histologically confirmed HGSC was included in
the current cohort. Additional inclusion criteria were normal
serum creatinine and/or glomerular filtration rate (GFR) [21],
at least three serum samples collected during primary ther-
apy and a serologically and/or radiologically detected HGSC
relapse [22]. All participants signed a written consent at the
time of enrollment and the study data were handled and
analyzed according to the information security laws of the
European Union. We followed the SPIRIT 2013 guideline
when applicable (Supplementary data) [23].
A team of gynecologic oncologists evaluated the up-front
cytoreductibility and patients underwent a treatment scheme
of either primary debulking surgery (PDS) with subsequent
chemotherapy (N¼ 58) or if estimated inoperable in diagnos-
tic laparoscopy, neoadjuvant chemotherapy (NACT) with
interval debulking surgery (IDS) and adjuvant chemotherapy
(N¼ 85) (Table 1). In the NACT group, 13 patients did not
have debulking surgery due to progressive disease or gen-
eral frailty. The operating gynecologic oncologist assessed
the disease stage as stated by the International Federation of
Gynecology and Obstetrics (FIGO) 2014 classification and a
pathologist confirmed it from tissue biopsies. The operating
team recorded the disease spread in the abdominal cavity
and retroperitoneum to calculate a previously described dis-
ease dissemination score (range 0–21) (Table S1) [24]. The
disease dissemination score showed prognostic value in a
previous study [24]. Patients were divided into a low tumor
load group (dissemination score 0–12) and a high tumor
load group (dissemination score 13–21). In all patients
treated with NACT, the disease dissemination score was cal-
culated at diagnostic laparoscopy, before the initiation of
chemotherapy. The operating team carefully assessed the
amount of residual disease after cytoreductive surgery. The
standard chemotherapy regimen included carboplatin and
paclitaxel. Sixteen patients received single agent carboplatin
because of general frailty. In 51 patients with advanced stage
disease, bevacizumab was combined with the primary
chemotherapy and continued as a maintenance therapy for
15 months or until first relapse (Table 1). In Finland, the first
line bevacizumab was available for high risk patients from
2013 forward. After primary therapy, the patients’ response
to primary therapy was evaluated by a multidisciplinary
tumor board with radiological and serological criteria [22].
Post-progression therapies included chemotherapy regimens
indicated for the treatment of HGSC, i.e., pegylated liposomal
doxorubicin (PLD), dose dense paclitaxel, and gemcitabine,
alone or in combination with a platinum agent and
bevacizumab.
Sample collection and analyses
Venous whole blood samples (10ml) for the HE4 and CA125
analyses were drawn into serum separation tubes at baseline
(before any oncological treatments), before each triweekly
cycle of primary chemotherapy and during standard follow
up visits at the outpatient clinic approximately every
3–6 months until first relapse. After incubation at room tem-
perature, the samples were centrifuged, and the separated
serum was aliquoted. We determined the serum CA125 con-
centrations with the clinically well-established ECLIA method
on the Cobas e 601 instrument or manually with the EIA
method (Fujirebio Diagnostics Inc., Malvern, PA, USA). In pre-
vious studies, these two methods have shown good correl-
ation [25]. Serum HE4 concentrations were similarly
determined with the EIA method (Fujirebio Diagnostics Inc.,
Malvern, PA, USA).
Statistical analyses
The biomarker medians, 25th and 75th quartiles for each
time point were calculated and the kinetics of the
Table 1. Patient characteristics.
N/median %/range
Patients 143
















No debulking surgery 13 9.1%
Primary chemotherapy
Carboplatinþ taxane 125 87.4%
Carboplatin single 16 11.2%
Other/unknown 2 1.4%
Bevacizumab maintenance 51 35.6%
Treatment outcome
Complete response 72 50.3%
Partial response 40 28.0%
Progressive disease 25 17.5%
Other 6 4.2%
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biomarkers during primary treatment were assessed. The bio-
markers kinetics were first evaluated separately for the NACT
and PDS groups with subsequent assessment of the com-
bined treatment arms (NACTþ PDS). We evaluated the distri-
bution of the biomarker values at each time point and made
a logarithmic transformation to correct for the non-Gaussian
skewness of the data. The biomarker means of baseline
serum samples were compared to different end points with
the t-test or the one-way analysis of variance (ANOVA). The
progression-free interval (PFI) was dichotomized to progres-
sion vs. no progression at a cut off time of 6 months to
evaluate the potential of the biomarkers to detect platinum
resistant progression. The nadir values for both HE4 and
CA125 were calculated, as the nadir value of CA125 has
been associated with the outcome of patients [26,27], and it
was defined as the lowest serum biomarker value during pri-
mary treatment or within three months after the conclusion
of treatments. The survival of different subgroups was eval-
uated in a time-to-event fashion with Kaplan–Meier’s estima-
tor curves and the statistical significance was evaluated with
the log rank test and/or Cox regression analysis. A stepwise
selection process was used in the multivariate survival ana-
lysis and the biomarker medians were used as cut off values
for the division of patients. Statistical analyses were done
with the IBM SPSS software (IBM Corp., Released 2019, IBM
SPSS Statistics for Macintosh, Version 26.0, IBM Corp.,
Armonk, NY, USA). p<.05 was considered significant.
Results
The serum baseline HE4 concentration correlates with
tumor burden
The longitudinal kinetics of serum CA125 and HE4 were simi-
lar during primary treatment in both treatment arms (PDS
and NACT) (Tables S2 and S3). The biomarker kinetics were
assessed carefully as some patients lacked serum samples in
an individual time point; however, we detected no
discrepancies in the longitudinal biomarker profiles. The
median baseline concentration of CA125 was marginally
higher in the PDS group compared to NACT (918.00U/ml
and 838.68 U/ml); however, the difference was not statistic-
ally significant (p¼.998). Similarly, the median baseline HE4
concentrations were comparable in the treatment arms (PDS:
750.52 pmol/l and NACT: 755.52 pmol/l, p¼.468). The treat-
ment arms were combined for the evaluation of biomarker
correlation to tumor burden. The baseline HE4 concentration
was associated with the tumor burden stated during surgery
(cytoreductive surgery in PDS patients and diagnostic lapar-
oscopy in NACT patients) as the serum HE4 was significantly
higher in patients with substantial tumor burden (dissemin-
ation score 13–21) than in patients with less extensive tumor
growth (dissemination score 0–12) (p<.0001, Figure 1). The
baseline CA125 was not to a similar extent associated with
tumor burden (p¼.067, Figure 1). Neither baseline CA125 nor
HE4 were significantly associated with the amount of residual
disease after cytoreductive surgery (p¼.641 and p¼.054,
respectively). However, the baseline HE4 level was found to
be trending toward statistical significance and it might be
clinically relevant in evaluating the feasibility of up front
debulking (R0 HE4 median 716.80 pmol/l, R> 0mm HE4
median 829.02 pmol/l). We detected no association with
baseline CA125 or HE4 to the PFI or OS.
The nadir CA125 and HE4 values predict platinum
resistant disease
The median PFI of patients was 9.53 months (interquartile
range 14.53 months). Patients receiving bevacizumab main-
tenance had a significantly longer PFI (median 14.20 months,
IQR 17.93) than patients treated with conventional chemo-
therapy only (median 9.10 months, IQR 12.47) (p¼.027, log
rank test). Nadir values were evaluable for 71 patients of
which 26 (36.62%) patients later developed rapid, platinum
resistant relapse within 6 months after the conclusion of pri-
mary chemotherapy. The nadir value was reached
Figure 1. Serum HE4 and CA125 levels at baseline in patients with (A) low tumor load and high tumor load: a strongly elevated HE4 concentration was signifi-
cantly associated with a higher tumor load (p<.0001) and (B) complete cytoreduction and >0mm residual disease. p<.05.
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simultaneously by the assays in 29 patients (40.85%). An ear-
lier HE4 nadir was detected in 19 (26.76%) patients and 23
(32.39%) patients had a later HE4 nadir compared to the
CA125 assay. The median nadir values were 14.00U/ml (IQR
20.00) and 56.58 pmol/l (IQR 54.17) for the CA125 and HE4
assays, respectively. In the platinum resistant subgroup, the
median CA125 and HE4 nadir values were 28.00U/ml (IQR
41.00) and 87.68 pmol/l (IQR 103.33), respectively. In contrast,
the median CA125 and HE4 nadirs in platinum sensitive sub-
group were 10.50U/ml (IQR 11.30) and 49.70 pmol/l (IQR
27.07), respectively. The nadir CA125 and HE4 levels were
significantly elevated in patients who developed platinum
resistant disease (p<.0001 both assays). The relationship of
the nadir values to the PFI was further examined in a time-
to-event fashion, and the Kaplan–Meier survival curves with
the log rank test verified the above-mentioned results
(CA125 p<.0001 and HE4 p¼.008) (Figure 2).
The serum HE4 concentration at progression predicts
the survival of patients
The follow up time of the study ranged from 1.5 months to
10.2 years, with a median follow up time of 2.5 years. The
follow-up times were shortest (below 6 months) for four
patients who developed fatal, rapidly progressing diseases
during NACT. After disease relapse, the median survival of
Figure 2. The Kaplan–Meier curves of progression free survival of patients with serum biomarker nadir values below and exceeding the nadir cut offs (medians).
The HE4 and CA125 nadir values >56.58 pmol/l and >14.00 U/ml were significantly correlated with platinum resistant progression (log rank test, p¼.008 and
p<.0001, respectively).
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patients was 16.0 months (survival post-progression, SPP). At
progression, the serum CA125 and HE4 concentrations
showed median values of 162.00U/ml and 199.20 pmol/l,
respectively. Interestingly, elevated serum HE4 concentrations
of >199.20 pmol/l at progression were significantly associ-
ated with a worse overall survival (univariate analysis
p<.0001, Table 2). No such correlation was detected with the
CA125 assay (p¼.13). In the univariate analysis, elderly
patients (>65 years) and patients treated with NACT had
worse overall survivals than younger patients and patients
treated with PDS (p¼.008 and p¼.002, respectively, Table 2);
however, the findings were not confirmed in the multivariate
analysis (p¼.19 and p¼.07, respectively, Table 2). In the
multivariate model, a HE4 serum concentration of
>199.20 pmol/l was independently associated to worse OS
(Table 2). Other covariates, such as disease stage, patients
age, treatment strategy, residual disease or
CA125> 162.00 U/ml at progression were not independently
associated to the OS of patients (Table 2).
As OS has been suggested to be a suboptimal end point
in cancer patients with a long SPP (>6 months) [28], we set
to further strengthen our results on the association of serum
HE4 at progression and survival utilizing SPP. Still, a serum
HE4 concentration of >199.20 pmol/l was significantly associ-
ated with a worse survival after the detection of progression
in both the univariate (log rank, p¼.001) and the multivariate
model (p¼.001) (Figure 3). An identical multivariate model
with the same covariates was used in the SPP and OS analy-
ses and the median HE4> 199.20 pmol/l at progression
remained the only independent predictor of shorter SPP.
Indeed, less than 50% of the patients with an HE4 concentra-
tion >199.20 pmol/l at progression were alive for a year
post-progression (Figure 3). In contrast, 50% of the patients
in the HE4< 199.20 pmol/l group were still alive two years
after the detection of progression (Figure 3). All patients that
were alive 3 years post-progression had a serum HE4 con-
centration below 199.20 pmol/l at the detection progression.
The serum CA125 concentration at progression was not sig-
nificantly associated with SPP (p¼.252) (Figure 3).
Discussion
In the current study, we present a longitudinal analysis on
the feasibility of HE4 as a complement to CA125 in HGSC
treatment monitoring and in the prognostic stratification of
patients. These results provide valuable fortification to the
previous studies on HE4 in HGSC patients. Our main findings
were the linkage between baseline HE4 and tumor burden,
and the prognostic potential of HE4 at the time of progres-
sion. This is to the best of our knowledge the first time these
findings have been reported.
The landscape of HGSC medical treatment is rapidly
changing due to the implementation of PARP inhibitors and
immunotherapy combinations to patient care. These novel
treatment options are specifically changing the notion of
recurrent disease and patients might live longer with a
slowly progressing or stable disease. Consequently, the prog-
nostic stratification of relapsed HGSC patients is a topic of
interest as it aids clinicians in choosing the most feasible
second line treatment. In the current study, HE4 showed
promise as a tempting auxiliary tool for CA125 in clinical tri-
als, as high HE4 serum levels at the time of relapse were
independently connected to survival.
In clinical trials, an objective, noninvasive assessment
method of tumor burden is highly needed for the timely
stratification of patients and in the monitoring of the treat-
ment response. In the present study, the baseline serum
level of HE4, unlike CA125, divided patients with high tumor
burden from patients with a less extensive tumor growth.
Previous studies have suggested the preoperative serum
level of HE4 to be predictive of the amount of residual dis-
ease in patients with ovarian cancer [29–31]. Our study did
not offer further support to these findings, although strongly
elevated serum HE4 levels were trending toward patients
with macroscopic residual disease. The association reported
in previous studies between baseline HE4 and the amount of
residual tumor is indicative of a connection between serum
HE4 and tumor burden; however, the anatomic location of
the tumor growth is central in determining the feasibility of
surgical removal and the amount of residual disease is not
necessarily determined by tumor volume.
The majority of HGSC patients relapse despite a satisfac-
tory response to primary therapy. The prognostic relevance
of the CA125 nadir has attracted clinical interest and the
connection between an elevated CA125 nadir and shorter
PFS has been described in earlier studies [32–34]. The prog-
nostic utility of the HE4 nadir has been less extensively
studied, but there is modest evidence on the prognostic dis-
advantage of a higher HE4 nadir [31]. Our results are in line
with these previous findings, as elevated CA125 and HE4
nadir values were significantly correlated with a shortened
PFI, specifically preceding a platinum resistant relapse.
Interestingly, the HE4 nadir was quite low in the current
Table 2. Hazard ratios with 95% confidence intervals (CIs) of OS by different clinical variables of HGSC patients (N¼ 40) using the log rank test and Cox’s pro-
portional hazards model.
Clinical variable Univariate p value Multivariate p value Multivariate HR 95% CI
Disease stage (FIGO 2014)
III vs. IV .12 .12 2.00 0.83–4.83
Residual tumor
>0mm .51 .34 1.53 0.64–3.64
Treatment strategy
PDS vs. NACT .002 .06 2.26 0.95–5.36
Age > 65 years .008 .19 1.76 0.75–4.11
CA125> 162.00 U/ml (median) at progression .13 .45 1.39 0.59–3.28
HE4> 199.20 pmol/l (median) at progression <.0001 .001 5.85 2.07–16.51
p<.05.
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cohort (57.23 pmol/l) compared to the validated cut off of
150.00 pmol/l recommended by the assay manufacturer for
postmenopausal patients.
The strengths of this study include the strict inclusion cri-
teria, prospective design, and uniform treatment strategies.
Also, the response and progression evaluation criteria were
carefully assessed for each patient in a clinical trial setup.
The number of patients in the progression analyses was
quite low (N¼ 40) and the exploratory results obtained in
the current study need further validation. The cohort con-
sisted of patients with advanced stage HGSC, and the prog-
nostic abilities of HE4 in early stage disease need to be
evaluated in future studies. A limitation of the study is the
use of two different immunoassays in the analysis of CA125,
although the assays have shown to be highly comparable in
previous research [25]. Another limitation is the long study
admission time and the use of various post-progression
chemotherapy regimens. However, this is typical in the clin-
ical setting and cannot be avoided either in clinical trials as
several factors affect the choice of the most appropriate
second line treatment, i.e., platinum sensitivity/resistance,
toxicity profile, distribution of disease, and patient preference
[35]. The long admission time may have influenced the crite-
ria for up-front cytoreduction and the quality of the surgery.
Figure 3. The Kaplan–Meier curves of survival post-progression (SPP) of patients (N¼ 40) with serum biomarker values below and exceeding the cut offs (medians)
at progression. A serum HE4 concentration of >199.20 pmol/l was significantly associated with worse survival (log rank test, p¼.001). A higher serum CA125 con-
centration at progression was not significantly associated with survival (p¼.252).
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However, the number of patients treated with NACT did not
change during the study period and the primary chemother-
apy regimen was quite homogeneous throughout the admis-
sion period.
The current study provides emerging evidence on the
prognostic benefit of serum HE4 measurement in patients
with HGSC. The measurement of serum HE4 appears to be a
feasible complementary tool in the evaluation of up front
cytoreductibility and the prognostic stratification of patients
at disease progression. In addition, the measurement of
serum HE4 could aid clinicians in a timely detection of plat-
inum resistant disease and offer support for the decision of
comprehensive genomic profiling to find individual targeted
therapies. Importantly, HE4 performed better or at least as
well as CA125 in all of the time points evaluated: at baseline,
nadir and in 1st relapse. Future studies with heterogeneous
cohorts, including patients receiving novel targeted thera-
pies, for the assessment of differences in the longitudinal
kinetics and prognostic abilities of conventional biomarkers
are warranted.
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